BLAINJECTIONINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
LYUMJEV (insulin lispro-aabc) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 2020.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog approved by FDA in June 2020 for treatment of diabetes mellitus. It is formulated with nifedipine to accelerate insulin absorption and onset of action compared to standard insulin lispro. The drug is administered via subcutaneous injection and is designed for flexible dosing in both mealtime and continuous subcutaneous insulin infusion (pump) therapy.
$15MPart D
PeakLYUMJEV is in peak lifecycle with modest Part D spend ($15M in 2023), indicating early-to-mid adoption phase where commercial teams focus on market penetration and formulary positioning against entrenched competitors.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Started Aug 2022
183 enrolled
Type 1 Diabetes
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®
Started May 2022
244 enrolled
Type 1 Diabetes
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Started Feb 2022
25 enrolled
Diabetes Mellitus, Type 1
Career Relevance
Working on LYUMJEV offers exposure to competitive insulin market dynamics, formulary strategy, and patient education around device-based delivery—critical skills in biologics commercialization. This is a mid-career growth opportunity in a mature but strategically important therapeutic area where differentiation and payer relationships drive success more than clinical novelty.
Worked on LYUMJEV at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.